IL161299A0 - Montelukast granule formulation - Google Patents

Montelukast granule formulation

Info

Publication number: IL161299A0
Authority: IL; Israel
Prior art keywords: granule formulation; montelukast; montelukast granule; formulation; relates
Prior art date: 2001-10-26

Application number

IL16129902A

Other languages

English (en)

Original Assignee

Merck Frosst Canada Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-26

Filing date

2002-10-22

Publication date

2004-09-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23329547&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL161299(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-10-22 Application filed by Merck Frosst Canada Inc filed Critical Merck Frosst Canada Inc

2004-09-27 Publication of IL161299A0 publication Critical patent/IL161299A0/xx

Links

UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 title 1
238000009472 formulation Methods 0.000 title 1
239000008187 granular material Substances 0.000 title 1
239000000203 mixture Substances 0.000 title 1
229960005127 montelukast Drugs 0.000 title 1
229960001951 montelukast sodium Drugs 0.000 abstract 1
LBFBRXGCXUHRJY-HKHDRNBDSA-M montelukast sodium Chemical compound [Na+].CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC([O-])=O)CC1 LBFBRXGCXUHRJY-HKHDRNBDSA-M 0.000 abstract 1
229940095353 oral granules Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Ophthalmology & Optometry (AREA)
Otolaryngology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

IL16129902A 2001-10-26 2002-10-22 Montelukast granule formulation IL161299A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US33954901P	2001-10-26	2001-10-26
PCT/CA2002/001604 WO2003035036A1 (en)	2001-10-26	2002-10-22	Montelukast granule formulation

Publications (1)

Publication Number	Publication Date
IL161299A0 true IL161299A0 (en)	2004-09-27

Family

ID=23329547

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL16129902A IL161299A0 (en)	2001-10-26	2002-10-22	Montelukast granule formulation

Country Status (26)

Country	Link
US (2)	US20030096840A1 (de)
EP (1)	EP1441701B1 (de)
JP (1)	JP4420671B2 (de)
KR (1)	KR101094084B1 (de)
CN (1)	CN100591329C (de)
AT (1)	ATE385781T1 (de)
AU (1)	AU2002333134B2 (de)
BR (1)	BR0213477A (de)
CA (1)	CA2463947C (de)
CY (1)	CY1107400T1 (de)
DE (1)	DE60225040T2 (de)
DK (1)	DK1441701T3 (de)
EC (1)	ECSP045082A (de)
EG (1)	EG24380A (de)
ES (1)	ES2298431T3 (de)
HR (1)	HRP20040367B1 (de)
HU (1)	HUP0401670A3 (de)
IL (1)	IL161299A0 (de)
MX (1)	MXPA04003856A (de)
MY (1)	MY148466A (de)
NO (1)	NO20042167L (de)
PE (1)	PE20030638A1 (de)
PT (1)	PT1441701E (de)
SI (1)	SI1441701T1 (de)
WO (1)	WO2003035036A1 (de)
ZA (1)	ZA200402584B (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040192660A1 (en) *	2003-03-12	2004-09-30	Mullally John P.	Protocol for improving vision
EP1863476B1 (de) *	2005-03-16	2016-02-03	MEDA Pharma GmbH & Co. KG	Kombination aus anticholinergika und leukotrien-rezeptorantagonisten zur behandlung von atemwegserkrankungen
CN100500149C (zh) *	2005-06-22	2009-06-17	晟德大药厂股份有限公司	白三烯素拮抗剂口服液组成
CA2629904C (en)	2005-11-28	2018-07-10	Imaginot Pty Ltd.	Oral therapeutic compound delivery system
PT1976522E (pt)	2005-12-30	2013-09-09	Krka Tovarna Zdravil D D Novo Mesto	Composição farmacêutica contendo montelucaste
CA2635841A1 (en) *	2006-02-09	2007-08-16	Teva Pharmaceutical Industries Ltd.	Stable pharmaceutical formulations of montelukast sodium
CA2661576A1 (en)	2006-09-26	2008-04-03	Taro Pharmaceuticals North America, Inc.	Stabilizing compositions for antibiotics and methods of use
CA2719246A1 (en) *	2008-03-26	2009-10-01	Taro Pharmaceuticals North America, Inc.	Stabilizing lipid compositions for oral pharmaceutical agents
US20100286045A1 (en)	2008-05-21	2010-11-11	Bjarke Mirner Klein	Methods comprising desmopressin
US11963995B2 (en)	2008-05-21	2024-04-23	Ferring B.V.	Methods comprising desmopressin
PL2712622T3 (pl)	2008-05-21	2017-01-31	Ferring B.V.	Ulegająca rozpadowi w ustach desmopresyna do zwiększania początkowego okresu snu niezakłócanego przez nokturię
WO2009153305A2 (en) *	2008-06-19	2009-12-23	Sandoz Ag	Pharmaceutical compositions of montelukast sodium
EP2327424A4 (de)	2008-08-18	2014-10-01	Mitsubishi Shoji Foodtech Co Ltd	Neuer hilfsstoff für mannitoltablettierung
JO3112B1 (ar)	2010-03-29	2017-09-20	Ferring Bv	تركيبة دوائية سريعة التحلل
NZ706991A (en)	2010-03-29	2016-08-26	Ferring Bv	A fast dissolving pharmaceutical composition
FR2967066B1 (fr) *	2010-11-04	2013-06-14	Ethypharm Sa	Utilisation par voie sublinguale de microgranules non comprimes
CN102085187B (zh) *	2011-01-27	2012-01-11	海南美大制药有限公司	孟鲁司特钠脂质体固体制剂
KR20140108627A (ko)	2011-07-26	2014-09-12	썬 파마 어드밴스트 리서치 컴패니 리미티드	퀴놀린-, 퀸옥살린 또는 벤조티아졸계 시스테이닐 류코트리엔 길항물질 (ltc4)
RU2633640C2 (ru)	2011-09-16	2017-10-16	Ферринг Б.В.	Быстрорастворимая фармацевтическая композиция
WO2013077829A1 (en)	2011-11-21	2013-05-30	Mahmut Bilgic	Water-soluble pharmaceutical granules
CA2878784A1 (en)	2012-07-12	2014-01-16	Ferring B.V.	Diclofenac formulations
WO2014012954A1 (en)	2012-07-18	2014-01-23	Takeda Gmbh	Treatment of partly controlled or uncontrolled severe asthma
US20140072628A1 (en) *	2012-09-12	2014-03-13	Glenmark Generics Ltd.	Stable pharmaceutical composition of saxagliptin
CN103520129B (zh) *	2013-10-15	2020-07-31	天垚医药科技发展（上海）有限公司	一种孟鲁斯特钠脉冲释放制剂
CN103520130B (zh) *	2013-10-15	2020-08-04	天垚医药科技发展（上海）有限公司	孟鲁斯特钠择时控释片及其制备方法
CN103520136B (zh) *	2013-10-15	2020-07-31	天垚医药科技发展（上海）有限公司	孟鲁斯特钠脉冲胶囊及其制备方法
CN104644564A (zh) *	2013-11-25	2015-05-27	天津汉瑞药业有限公司	一种含孟鲁司特钠的稳定的颗粒制剂及其制备方法
CN103655497B (zh) *	2013-12-18	2018-05-29	北京华禧联合科技发展有限公司	一种孟鲁司特钠口腔崩解片及其制备方法
WO2015110394A1 (en)	2014-01-22	2015-07-30	Takeda Gmbh	Treatment of partly controlled or uncontrolled severe asthma with a pde4 inhibitor (and in combination with a leukotriene modifier)
CN103720672B (zh) *	2014-01-26	2016-03-16	新疆特丰药业股份有限公司	孟鲁司特钠咀嚼片及其粉末直接压片制备方法
CN104840427B (zh) *	2014-02-13	2017-09-29	长春海悦药业股份有限公司	一种含有孟鲁司特钠的药物组合物
WO2016148455A2 (ko) *	2015-03-13	2016-09-22	경희대학교 산학협력단	몬테루카스트의 생체이용률을 개선시키기 위한 방법
JP6489435B2 (ja) *	2015-04-20	2019-03-27	高田製薬株式会社	モンテルカストナトリウム顆粒製剤
CN107595783A (zh) *	2017-06-01	2018-01-19	合肥远志医药科技开发有限公司	一种孟鲁司特钠颗粒及其制备方法
CN109833302A (zh) *	2017-11-29	2019-06-04	扬子江药业集团有限公司	一种稳定的孟鲁司特钠咀嚼片及其制备方法
CN110787139A (zh) *	2018-08-01	2020-02-14	北京万全德众医药生物技术有限公司	一种孟鲁司特钠药物组合物
EP3846792A4 (de)	2018-09-06	2022-10-12	Innopharmascreen Inc.	Verfahren und zusammensetzungen zur behandlung von asthma oder morbus parkinson
CN111110679A (zh) *	2018-10-31	2020-05-08	长春海悦药业股份有限公司	一种含有孟鲁司特钠的药物组合物
CN111249238A (zh) *	2020-01-19	2020-06-09	安徽省先锋制药有限公司	一种孟鲁司特钠颗粒制剂方法
WO2022006470A1 (en)	2020-07-01	2022-01-06	Vanderbilt University	Methods of treatment for a kidney disease
WO2022011210A1 (en) *	2020-07-10	2022-01-13	Sean Downing	Treatment for severe acute respiratory illness associated with coronavirus
CN111840233B (zh) *	2020-07-29	2022-05-06	浙江诺得药业有限公司	一种孟鲁司特钠固体分散体、其制备方法及其应用
CN115770222B (zh) *	2021-09-05	2025-09-26	山东新时代药业有限公司	一种孟鲁司特钠颗粒剂及其制备方法
CN114224847B (zh) *	2021-12-07	2023-09-15	哈尔滨珍宝制药有限公司	一种孟鲁司特钠颗粒的制备方法
CN114425040A (zh) *	2022-02-24	2022-05-03	佑华医药科技有限公司	一种孟鲁司特钠颗粒的制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1561301A (en) *	1976-01-02	1980-02-20	Beecham Group Ltd	Orally administrable pharmaceutical composition
NZ230763A (en)	1988-09-27	1991-10-25	Takeda Chemical Industries Ltd	Production of granules having a core by spraying the cores with a dispersion of hydroxypropylcellulose, optionally incorporating an active ingredient
FI894611L (fi)	1988-09-30	1990-03-31	May & Baker Ltd	Granulaera farmaceutiska preparat.
DK0390435T3 (da) *	1989-03-29	1994-03-21	Takeda Chemical Industries Ltd	Blanding indeholdende en forbindelse fra vitamin B gruppen, og fremstilling deraf
JP2800242B2 (ja)	1989-03-30	1998-09-21	大正製薬株式会社	粒剤の製造方法
US5565473A (en) *	1990-10-12	1996-10-15	Merck Frosst Canada, Inc.	Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
JP2820829B2 (ja)	1991-03-07	1998-11-05	武田薬品工業株式会社	有核散剤およびその製造方法
JPH0967247A (ja)	1995-08-31	1997-03-11	Taisho Pharmaceut Co Ltd	均一な微粒子製剤の製造方法
WO1997016173A1 (en) *	1995-11-02	1997-05-09	Merck Frosst Canada Inc.	New technology for wet granulation
IL125446A0 (en) *	1996-02-08	1999-03-12	Merck & Co Inc	Pharmaceutical composition for the treatment of asthma allergy and inflammation
US5869098A (en)	1997-08-20	1999-02-09	Fuisz Technologies Ltd.	Fast-dissolving comestible units formed under high-speed/high-pressure conditions
DK1041990T3 (da) *	1997-12-23	2006-10-02	Schering Corp	Præparat til behandling af respiratoriske sygdomme og hudsygdomme med mindst en leukotrien-antagonist og mindst et antihistamin
US6224907B1 (en) *	1998-03-06	2001-05-01	Alza Corporation	Anti-asthma therapy
US6221880B1 (en) *	1998-10-09	2001-04-24	Schering Corporation	Composition and method for treating allergic diseases
US6103735A (en) *	1998-10-09	2000-08-15	Schering Corporation	Composition and method for treating allergic diseases
AT413647B (de)	1998-11-26	2006-04-15	Sandoz Ag	Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten
US6248363B1 (en)	1999-11-23	2001-06-19	Lipocine, Inc.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6491949B2 (en) *	2000-01-14	2002-12-10	Osmotica Corp.	Osmotic device within an osmotic device
US20030031720A1 (en)	2000-02-24	2003-02-13	Tobias Laich	Method for producing pharmaceutical dosage forms
US6316029B1 (en) *	2000-05-18	2001-11-13	Flak Pharma International, Ltd.	Rapidly disintegrating solid oral dosage form

2002
- 2002-10-17 MY MYPI20023875A patent/MY148466A/en unknown
- 2002-10-22 CA CA002463947A patent/CA2463947C/en not_active Expired - Lifetime
- 2002-10-22 HR HRP20040367AA patent/HRP20040367B1/xx not_active IP Right Cessation
- 2002-10-22 KR KR1020047006095A patent/KR101094084B1/ko not_active Expired - Lifetime
- 2002-10-22 PT PT02801836T patent/PT1441701E/pt unknown
- 2002-10-22 BR BR0213477-2A patent/BR0213477A/pt not_active Application Discontinuation
- 2002-10-22 HU HU0401670A patent/HUP0401670A3/hu unknown
- 2002-10-22 ES ES02801836T patent/ES2298431T3/es not_active Expired - Lifetime
- 2002-10-22 AT AT02801836T patent/ATE385781T1/de active
- 2002-10-22 MX MXPA04003856A patent/MXPA04003856A/es active IP Right Grant
- 2002-10-22 DE DE60225040T patent/DE60225040T2/de not_active Expired - Lifetime
- 2002-10-22 WO PCT/CA2002/001604 patent/WO2003035036A1/en not_active Ceased
- 2002-10-22 AU AU2002333134A patent/AU2002333134B2/en not_active Expired
- 2002-10-22 EP EP02801836A patent/EP1441701B1/de not_active Revoked
- 2002-10-22 JP JP2003537603A patent/JP4420671B2/ja not_active Expired - Lifetime
- 2002-10-22 CN CN02821212A patent/CN100591329C/zh not_active Expired - Lifetime
- 2002-10-22 DK DK02801836T patent/DK1441701T3/da active
- 2002-10-22 SI SI200230670T patent/SI1441701T1/sl unknown
- 2002-10-22 IL IL16129902A patent/IL161299A0/xx unknown
- 2002-10-23 EG EG2002101164A patent/EG24380A/xx active
- 2002-10-24 PE PE2002001047A patent/PE20030638A1/es active IP Right Grant
- 2002-10-24 US US10/279,595 patent/US20030096840A1/en not_active Abandoned
2004
- 2004-04-01 ZA ZA2004/02584A patent/ZA200402584B/en unknown
- 2004-04-23 EC EC2004005082A patent/ECSP045082A/es unknown
- 2004-05-25 NO NO20042167A patent/NO20042167L/no not_active Application Discontinuation
2008
- 2008-02-07 US US12/069,124 patent/US8007830B2/en not_active Expired - Fee Related
- 2008-04-17 CY CY20081100434T patent/CY1107400T1/el unknown

Also Published As

Publication number	Publication date
HUP0401670A3 (en)	2008-08-28
DE60225040T2 (de)	2009-02-26
CA2463947A1 (en)	2003-05-01
KR20040047961A (ko)	2004-06-05
US20080131516A1 (en)	2008-06-05
DE60225040D1 (de)	2008-03-27
CA2463947C (en)	2009-05-19
BR0213477A (pt)	2004-11-03
ECSP045082A (es)	2004-06-28
EP1441701A1 (de)	2004-08-04
KR101094084B1 (ko)	2011-12-15
DK1441701T3 (da)	2008-05-26
JP4420671B2 (ja)	2010-02-24
NO20042167L (no)	2004-05-25
ZA200402584B (en)	2005-06-29
US20030096840A1 (en)	2003-05-22
WO2003035036A1 (en)	2003-05-01
EG24380A (en)	2009-04-05
CY1107400T1 (el)	2012-12-19
ATE385781T1 (de)	2008-03-15
HRP20040367A2 (xx)	2005-06-30
MY148466A (en)	2013-04-30
HRP20040367B1 (en)	2012-07-31
US8007830B2 (en)	2011-08-30
SI1441701T1 (sl)	2008-08-31
JP2005510497A (ja)	2005-04-21
AU2002333134B2 (en)	2007-08-02
ES2298431T3 (es)	2008-05-16
MXPA04003856A (es)	2004-07-08
CN100591329C (zh)	2010-02-24
HUP0401670A2 (hu)	2008-05-28
PE20030638A1 (es)	2003-07-21
EP1441701B1 (de)	2008-02-13
PT1441701E (pt)	2008-04-07
CN1575163A (zh)	2005-02-02

Publication	Publication Date	Title
EG24380A (en)	2009-04-05	Granule formulation
AU3652102A (en)	2002-06-11	Compounds and their uses
TW200510325A (en)	2005-03-16	2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
TNSN07235A1 (en)	2008-11-21	Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride
MXPA04003796A (es)	2004-07-30	Tioacetamidas sustituidas.
IL150257A0 (en)	2002-12-01	Galactomaninan oligosaccharides, pharmaceutical compositions containing the same and methods for the production thereof
PL370292A1 (en)	2005-05-16	Formulations for oral administration of active compounds
AP1787A (en)	2007-10-04	Novel perindopril salt and pharmaceutical compositions containing same.
DK1458377T3 (da)	2006-06-12	Farmaceutiske sammensætninger indeholdende tegaserod
ZA200404752B (en)	2005-04-26	6-aminomorphinane derivatives method for the production and use thereof
MXPA03010158A (es)	2004-03-10	Sulfonamidas.
WO2002024695A3 (en)	2002-09-19	Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines
SE0200657D0 (sv)	2002-03-04	Novel Formulation
MXPA04003910A (es)	2004-07-23	Uso de irbesartan para la preparacion de medicamentos que son utiles para la prevencion o tratamiento de hipertension pulmonar.
DE60212130D1 (en)	2006-07-20	Carvedilolpolymorph
MXPA04006085A (es)	2004-09-27	Compuestos de isocromano para el tratamiento de trastornos del sistema nervioso central.
GB0309440D0 (en)	2003-06-04	Quinolone derivatives
SG144141A1 (en)	2008-07-29	Semi-solid systems containing azetidine derivatives
PL359727A1 (en)	2004-09-06	Crystalline pharmaceutical
NO20035138D0 (no)	2003-11-18	Fremgangsmåte til fremstilling av amorft natriumsilastatin
PL365687A1 (en)	2005-01-10	Novel trioxepan compounds
AU2002226616A8 (en)	2006-11-02	Preparation of pure 3-alkoxymethyl cephalosporins.
TW200603801A (en)	2006-02-01	Novel dialkoxy-imidazopyridines
AU2003216904A1 (en)	2003-10-20	Aqueous formulations of (2-hydroxymethyl-indanyl-4-oxy)-phenyl-4,4,4-trifluorobutane-1-sulfonate
GB0109520D0 (en)	2001-06-06	Use of (di-substituted-phenyl)-pyrimidinyl-imidazole derivatives as njk-inhibitors